PMID: 9171997Jun 1, 1997Paper

Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities

Genes, Chromosomes & Cancer
P AndreassonM Höglund

Abstract

Seventy-nine acute myeloid leukemias (AML) and myelodysplastic syndromes without cytogenetic evidence of 12p aberrations were investigated by fluorescence in situ hybridization with probes for ETV6 and CDKN1B (previously called TEL and KIP1, respectively) to ascertain whether abnormalities of these genes are frequently undetected by standard chromosome banding analyses and, if so, whether they are associated with specific karyotypic patterns and morphologic features. One of sixty cytogenetically aberrant myeloid malignancies, an AML with a complex karyotype including del(5q) and del(20q), showed a hemizygous interstitial deletion of the ETV6 and CDKN1B loci. No concomitant rearrangement of the other ETV6 allele was detected. Two of nineteen cytogenetically normal AML displayed a hemizygous interstitial deletion involving CDKN1B, but not ETV6. Thus, cryptic deletions of these genes seem to be rare in cytogenetically abnormal myeloid malignancies without 12p aberrations (2%), whereas they may be more frequent in karyotypically normal AML (10%). Furthermore, the present findings show that the deletions may be narrow, not including the ETV6 gene, and indirectly suggest that CDKN1B, or a closely located genomic segment, is the targe...Continue Reading

References

May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D PinkelJ W Gray
Mar 1, 1994·Genes, Chromosomes & Cancer·S P RomanaR Berger
Dec 1, 1994·Genes, Chromosomes & Cancer·F MertensN Mandahl
Jul 1, 1995·Cancer Genetics and Cytogenetics·E W SasserC Daeschner
Jan 1, 1995·Cytogenetics and Cell Genetics·M HöglundF Mitelman
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·T R GolubD G Gilliland
Jan 1, 1995·Genomics·H M KozmanN J Royle
Nov 1, 1993·Leukemia & Lymphoma·L LongoA Neri
Jan 1, 1996·European Journal of Haematology·I PanagopoulosF Mitelman
May 1, 1996·Genome Research·M BaensP Marynen
Aug 1, 1996·Molecular and Cellular Biology·T R GolubD G Gilliland

❮ Previous
Next ❯

Citations

Nov 20, 1997·Genes, Chromosomes & Cancer·P AndreassonM Höglund
Jan 22, 2004·Cancer Genetics and Cytogenetics·Jeanna WelbornPaula Walling
Apr 8, 1998·Cancer Genetics and Cytogenetics·P AndreassonM Höglund
Dec 9, 1998·Cancer Genetics and Cytogenetics·D GisselssonN Mandahl
Sep 15, 2005·International Journal of Cancer. Journal International Du Cancer·Ioannis PanagopoulosNils Mandahl
Jul 7, 2011·The Biochemical Journal·Xi MaDefa Li
Sep 22, 1999·Molecular and Cellular Biology·R FenrickS W Hiebert

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.